Selection of antibiotics for meticillin-resistant Staphylococcus pseudintermedius: Time to revisit some old drugs

Veterinary Dermatology

Volumn 23, Issue 4, 2012, Pages

  Papich, Mark G ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLASSIFICATION; DRUG EFFECT; MICROBIOLOGY; PENICILLIN RESISTANCE; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS;

ANIMALIA; CANIS FAMILIARIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PSEUDINTERMEDIUS;

EID: 84864145842     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2011.01030.x     Document Type: Article

References (62)

1. Weese JS, van Duijkeren E. Methicillin-resistant Staphylococcus aureus and Staphylococcus pseudintermedius in veterinary medicine. Vet Microbiol 2010; 140: 418-429.
2. Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008; 62(Suppl 1): i1-i9.
3. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evoluationary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005; 40: 562-573.
4. Gortel K, Campbell KL, Kakoma I et al. Methicillin resistance among staphylococci isolated from dogs. Am J Vet Res 1999; 60: 1526-1530.
5. Bemis DA, Jones RD, Hiatt LE et al. Comparison of tests to detect oxacillin resistance in Staphylococcus intermedius, Staphylococcus schleiferi, and Staphylococcus aureus isolates from canine hosts. J Clin Microbiol 2006; 44: 3374-3376.
6. Jones RD, Kania SA, Rohrbach BW et al. Prevalence of oxacillin- and multidrug-resistant staphylococci in clinical samples from dogs: 1, 772 samples (2001-2005). J Am Vet Med Assoc 2007; 230: 221-227.
7. Devriese LA, Vancanneyt M, Baele M et al. Staphylococcus pseudintermedius sp. nov., a coagulase-positive species from animals. Int J Syst Evol Microbiol 2005; 55: 1569-1573.
8. Sasaki T, Kikuchi K, Tanaka Y et al. Reclassification of phenotypically identified Staphylococcus intermedius strains. J Clin Microbiol 2007; 45: 2770-2778.
9. Bemis DA, Jones RD, Frank LA et al. Evaluation of susceptibility test breakpoints used to predict mecA-mediated resistance in Staphylococcus pseudintermedius isolated from dogs. J Vet Diagn Invest 2009; 21: 53-58.
10. Dancer SJ. The effect of antibiotics on methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2008; 61: 246-253.
11. Harbarth S, Samore MH. Interventions to control MRSA: high time for time-series analysis? J Antimicrob Chemother 2008; 62: 431-433.
12. Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals; Approved Standard, 3rd edition. CLSI document M31-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
13. Papich MG. Proposed changes to Clinical Laboratory Standards Institute interpretive criteria for methicillin-resistant Staphylococcus pseudintermedius isolated from dogs. J Vet Diagn Invest 2010; 22: 160.
14. Schissler JR, Hillier A, Daniels JB et al. Evaluation of Clinical Laboratory Standards Institute interpretive criteria for methicillin-resistant Staphylococcus pseudintermedius isolated from dogs. J Vet Diagn Invest 2009; 21: 684-688.
15. Perreten V, Kadlec K, Schwarz S et al. Clonal spread of methicillin-resistant Staphylococcus pseudintermedius in Europe and North America: an international multicentre study. J Antimicrob Chemother 2010; 65: 1137-1144.
16. Campbell KL. Sulphonamides: updates on use in veterinary medicine. Vet Dermatol 1999; 10: 205-215.
17. Ihrke PJ, Papich MG, DeManuelle TC. The use of fluoroquinolones in veterinary dermatology. Vet Dermatol 1999; 10: 193-204.
18. Noli C, Boothe D. Macrolides and lincosamides. Vet Dermatol 1999; 10: 217-223.
19. Kadlec K, van Duijkeren E, Wagenaar JA et al. Molecular basis of rifampicin resistance in methicillin-resistant Staphylococcus pseudintermedius isolates from dogs. J Antimicrob Chemother 2011; 66: 1236-1242.
20. Sentürk S, Özel E, Sen A. Clinical efficacy of rifampicin for treatment of canine pyoderma. Acta Vet Brno 2005; 74: 117-122.
21. Papich MG. Saunders Handbook of Veterinary Drugs, 3rd edition. St Louis, MO: Elsevier-Saunders, 2011; 266-268 and 684-686.
22. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-292.
23. Falagas ME, Bliziotis IA, Fragoulis KN. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Control 2007; 35: 106-114.
24. Reitman ML, Chu X, Cai S et al. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther 2011; 89: 234-242.
25. Lee KH, Shin JG, Chong WS et al. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. Eur J Clin Pharmacol 1993; 45: 287-289.
26. Papich MG, Davidson G. Doxycycline potency after storage in a compounded formulation for animals. J Vet Intern Med 2011; 25: 741 (Abstract P-5 of the ACVIM Forum).
27. Carlborg B, Densert O, Lindqvist C. Tetracycline induced esophageal ulcers. A clinical and experimental study. Laryngoscope 1983; 93: 184-187.
28. Carlborg B, Densert O. Esophageal lesions caused by orally administered drugs: an experimental study in the cat. Eur Surg Res 1980; 12: 270-282.
29. Graham JP, Lipman AH, Newell SM et al. Esophageal transit of capsules in clinically normal cats. Am J Vet Res 2000; 61: 655-657.
30. Westfall DS, Twedt DC, Steyn PF et al. Evaluation of esophageal transit of tablets and capsules in 30 cats. J Vet Intern Med 2001; 15: 467-470.
31. Wilson RC, Kitzman JV, Kemp DT et al. Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. Am J Vet Res 1985; 46: 1316-1318.
32. Mercer HD, Geleta JN, Kramer J. Chloramphenicol blood concentration studies in dogs. J Am Vet Med Assoc 1971; 158: 47-52.
33. Knifton A. The responsible use of chloramphenicol in small animal practice. 1. Pharmacological considerations. J Small Anim Pract 1987; 28: 537-542.
34. Clark CH. Chloramphenicol dosage. Mod Vet Pract 1978; 59: 749-754.
35. Davis LE, Davis CN. Dosage regimens of chloramphenicol in domesticated animals. J S Afr Vet Assoc 1974; 45: 77-79.
36. Watson ADJ. Chloramphenicol plasma levels in the dog: a comparison of oral, subcutaneous and intramuscular administration. J Small Anim Pract 1972; 13: 147-151.
37. Watson ADJ. Chloramphenicol plasma levels in the dog: multiple oral and intramuscular administration. J Small Anim Pract 1972; 13: 153-157.
38. Eads FE. Blood level studies in dogs following the administration of chloromycetin. Am J Vet Res 1952; 47: 204-206.
39. Bergt G, Stowe CM. Comparison of bioavailability of two chloramphenicol preparations in dogs after intramuscular injection. Am J Vet Res 1975; 36: 1481-1482.
40. Watson AD, McDonald PJ. Distribution of chloramphenicol in some tissues and extravascular fluids of dogs after oral administration. Am J Vet Res 1976; 37: 557-559.
41. Watson AD. Plasma chloramphenicol levels in dogs after the administration of four different oral preparations of chloramphenicol. Aust Vet J 1973; 49: 460-462.
42. Watson ADJ. Chloramphenicol in the dog: observations of plasma levels following oral administration. Res Vet Sci 1974; 16: 147-151.
43. Watson ADJ. Further observations on chloramphenicol toxicosis in cats. Am J Vet Res 1980; 41: 293-294.
44. Watson ADJ. Chloramphenicol toxicity in dogs. Res Vet Sci 1977; 23: 66-69.
45. Settepani JA. The hazard of using chloramphenicol in food animals. J Am Vet Med Assoc 1984; 184: 930-931.
46. Aidasani D, Zaya MJ, Malpas PB et al. In vitro drug-drug interaction screens for canine veterinary medicines: evaluation of cytochrome P450 reversible inhibition. Drug Metab Dispos 2008; 36: 1512-1518.
47. Kukanich B, Kukanich KS, Rodriguez JR. The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. Vet Anaesth Analg 2011; 38: 224-230.
48. Akesson CE, Linero PEM. Effect of chloramphenicol on serum salicylate concentrations in dogs and cats. Am J Vet Res 1982; 43: 1471-1472.
49. Sanders JE, Yeary RA, Fenner WR et al. Interaction of phenytoin with chloramphenicol or pentobarbital in the dog. J Am Vet Med Assoc 1979; 175: 177-180.
50. Adams HR, Dixit BN. Prolongation of pentobarbital anesthesia by chloramphenicol in dogs and cats. J Am Vet Med Assoc 1970; 156: 902-905.
51. Drusano GL, Ambrose PG, Bhavnani SM et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45: 753-760.
52. Maglio D, Nightingale CH, Nicolau DP. Extended interval aminoglycoside dosing: from concept to clinic. Int J Antimicrob Agents 2002; 19: 341-348.
53. Konig C, Simmen HP, Blaser J. Bacterial concentrations in pus and infected peritoneal fluid - implication of bactericidal activity of antibiotics. J Antimicrob Chemother 1998; 42: 227-232.
54. Papich MG, Riviere JE. Aminoglycoside antibiotics. In: Riviere JE, Papich MG, eds. Veterinary Pharmacology and Therapeutics, 9th edition. Ames, Iowa, USA: Wiley-Blackwell Publishing, 2009; 915-944.
55. Neely M, Jelliffe R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol 2008; 48: 1081-1091.
56. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus- an antibiotic enters obsolescence. Clin Infect Dis 2007; 44: 1543-1548.
57. Gould IM. Clinical activity of anti-gram-positive agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2011; 68(Suppl 4): iv17-iv21.
58. Slatter JG, Adams LA, Bush EC et al. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 2002; 32: 907-924.
59. Bhamidipati RK, Dravid PV, Mullangi R et al. Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones. Xenobiotica 2004; 36: 571-579.
60. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 2011; 66(Suppl 4): iv7-iv15.
61. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006; 58: 256-265.
62. Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother 2011; 66(Suppl 3): iii11-iii18.